מעכבים סלקטיביים של ספיגה חוזרת של סרטונין והסיכון לתסמונת רגל חסרת מנוח
השפעת מגנזיום על פינוי לקטאט במטופלים עם אלח דם חמור במצב אנוש
בינה מלאכותית בתחום רפואת המשפחה – המחקר עדיין בחיתוליו
חסמים בטיפול הפליאטיבי במגיפת הקורונה
איך השפיעו המלצות ה-USPSTF על התוצאים לאחר כריתת ערמונית?
Subscribe to Medic
The only Israeli drug index for medical professionals
Search all the drugs distributed in Israel
Antihistamine. Dimethindene Maleate 1 mg/ml. ORAL DROPS: 20 ml x 1 mg/ml (0.05
mg/drop). 20-40 drops 3 x dly. Child:
about 0.1 mg/kg bdy wt. 1 mth-1 yr:
3-10 drops 3 x dly, 1-3 yrs: 10-15 drops
3 x dly; 3-12 yrs: 15-20 drops 3x dly.
Prurit., allerg. conds.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
Analgesic, Antipyretic, Opioid. Caffeine 50 mg, Codeine Phosphate 15 mg, Paracetamol 500 mg. CAPLETS: 12, 24. 1 capl. × 3-4 times/day. For severe pains - 2 capl. 3-4 times/day. Do not exceed a dosage of 8 capl. in 24 hrs. See lit.
For the relief of pain and coughs and for the reduction of fever accompanied by pain.
C/I: Hypersens. 1st & 3rd trim. of preg. Lact. Child. under 12 yrs. old. Adolesc. over 12 yrs. old and under 18 yrs. old after surg. remov. of their tonsils or adenoids. Concom. use with medic. contain. paracetamol /codeine. Pts. with respirat. depress. Pts. who are known as ultra-rapid metabolizer.
Cephalosporins. Cephalexin (as monohydrate) 500 mg. CAPS: 10, 20 x 500 mg. 1-4 g per
day in div. doses. Child: 25-50 mg/kg
bdy. wt. dly. in div. doses.
Infects. due to cephalexin suscept. organ.
C/I: Hypersens. to cephalexin. See lit.
Hematinic. Ferrous Fumarate 100 mg, Folic Acid 400 mcg. TABS: 30. Anem: 1-3 tabs dly. Maint.
folic acid levels: 1 tab dly. Not for child
under 12 yrs.
Anem., maint. folic acid levels.
Drug
Antipsychotic. Zuclopenthixol 20 mg/ml. ORAL DROPS: 20 ml x 20 mg/ml (1 drop
= 1 mg). 20-30 mg dly. in div. doses.
Maint: 20-50 mg dly. Max: 150 mg dly.
Elderly: May have to reduce. Child: Not
recommend.
Acute schizophrenia and other acute
psychoses.
C/I: As for other neuroleptics, intol. to
thioxanthenes. See lit.
Antibacterial, Antifungal, Corticosteroid. Gramicidin 0.25 mg/g, Neomycin Sulphate 2.5 mg/g, Nystatin 100000 IU/g, Triamcinolone 1 mg/g. OINT.: 5, 15 g. Apply 2-3 x dly.
See lit.
Allerg. and infect. dermatit., eczema,
cutan. candidiasis, anogenital prurit.
C/I: T.B., herpes simplex, vaccinia,
varicella, lesions not suscept. to nystatin.
GnRH Antagonist. Elagolix (as sodium) 150 mg, 200 mg. F.C. TABS: 28×150mg, 56×200mg. Init. tmt. with 150 mg×1/d, max. tmt. duration-24 mnths.
Consider initiat. tmt. with 200 mg×2/d max. tmt. duration- 6 mnths., with coexist. cond.- dyspareunia.
Init. tmt. with Elagolix 150 mg×1/d. Use of 200 mg×2/d is not recommended, max. tmt. duration- 6 mnths., with coexist. cond.- moder. hep. impair. (Child-Pugh Class B).
Hep. Impair.: No dosage adjust. of Elagolix is require. in women with mild hep. impair. (Child-Pugh A). Elagolix 150 mg×1/d is recomm. for women with moder. hep. impair. (Child-Pugh B) with the duration of tmt. limited to 6 mnths. Use of Elagolix 200 mg×2/d is not recommend. for women with moder. hep. impair. See lit.
Management of moder.–seve. pain assoc. with endometriosis.
C/I: With Hypersens. Preg. Women with known osteoporosis. Women with sev. hep. impair (Child-Pugh C).
IL-ELAG-200014-june2020
Monoclonal Antibody. Trastuzumab 150, 420 mg. VIAL (Pwdr. for concentrate for sol. for infus.): 1. Dosage must be ajust. individ accord. pt. med. cond. and indication.
Tmt. of pts. with metast. breast canc. who have tumors that overexpress HER2;
As a single agent, for the tmt. of those pts. who have received one or more chemother. regim. for their metast. dis.
In comb. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metast. dis.
In comb. with an aromatase inhib. for the tmt. of postmenopaus. pt. with hormonereceptor positive metast. breast canc.
Early breast cancer (EBC) – pts. with HER2 positive early breast cancer follow. surg. and chemother. (neoadjuv./ adjuvant) either alone or in comb. with chemother. exclude. anthracyclines.
The drug should only be used in pts. whose tumors have either HER2 overexpres. or HER2 gene amplificat. as determ. by an accurate and validated assay. HER2 Metastat. gast. cancer (MGC)- in comb. with capecitabine or 5-fluorouracil and cisplatin is indic. for the tmt. of pts. with HER2-positive metast. adenocarcinoma of the stomach or gastroesophag. junction who have not received prior anti-cancer tmt. for their metastat. dis.
Trastuzumab should only be used in pts. with metastat. gast. cancer (MGC) whose tumours have HER2 overexpres. as defined by IHC 2+ and a confirmatory FISH+ result, or IHC 3+, as determ. by an accurate and validated assay.
C/I: Hypersens. Severe dyspnea at rest due to complicat. of advanced malig. or require. supplement. oxygen ther.
(ADP-ribose) polymerase (PARP) inhibitor. Talazoparib Tosylate 0.25 mg, 1 mg. HARD CAPS.: 30×1 mg, 60×0.25 mg. 1 mg ×1/d taken orally, with/without food.
The 0.25 mg cap. is available for dose reduction.
Pts. should be treated until dis. progres. or unaccept. toxicity occurs.
To avoid contact with the caps. content, Talazoparib cap. should be swallow. whole, and must not be opened or dissolve.
If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time.
Dose reduct. levels for adverse react. -See lit.
Tmt. of adult pts. with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epiderm. growth factor receptor 2 (HER2)-negative locally advanc. or metastat. breast cancer.
C/I: Hypersens.
